These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20820759)

  • 1. Angiotensin II type 1 receptor blockers improve insulin sensitivity in patients with schizophrenia being treated with olanzapine.
    Yamashita H; Yoda H; Kuroki N; Kuwabara M; Odagaki Y; Kazawa T; Toyoshima R; Maruki T
    Psychopharmacology (Berl); 2011 Jan; 213(1):1-9. PubMed ID: 20820759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome.
    Ichikawa Y
    Intern Med; 2007; 46(17):1331-6. PubMed ID: 17827829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE).
    Mori Y; Tanaka T; Matsuura K; Yokoyama J; Utsunomiya K
    Adv Ther; 2011 Aug; 28(8):698-706. PubMed ID: 21744143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telmisartan, an angiotensin II type-1 receptor blocker, improved insulin resistance in a schizophrenic patient treated with olanzapine: a case report.
    Yamashita H; Yoda H; Maruki T; Toyoshima R
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):308-10. PubMed ID: 17884270
    [No Abstract]   [Full Text] [Related]  

  • 5. The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: Abdominal fat Depot Intervention Program of Okayama (ADIPO).
    Murakami K; Wada J; Ogawa D; Horiguchi CS; Miyoshi T; Sasaki M; Uchida HA; Nakamura Y; Makino H
    Diab Vasc Dis Res; 2013 Jan; 10(1):93-6. PubMed ID: 22561230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dimethylarginine levels.
    Tomiyama H; Yamada J; Koji Y; Shiina K; Yoshida M; Yamashina A
    Am J Hypertens; 2007 Dec; 20(12):1305-11. PubMed ID: 18047921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis.
    Georgescu EF; Ionescu R; Niculescu M; Mogoanta L; Vancica L
    World J Gastroenterol; 2009 Feb; 15(8):942-54. PubMed ID: 19248193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
    Yamagishi S; Takeuchi M
    Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
    Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
    Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
    Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
    Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.
    Derosa G; Cicero AF; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Ferrari I; Gravina A; Fogari R
    Hypertens Res; 2006 Nov; 29(11):849-56. PubMed ID: 17345784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
    Nishida Y; Takahashi Y; Susa N; Kanou N; Nakayama T; Asai S
    Cardiovasc Diabetol; 2013 Nov; 12():159. PubMed ID: 24180232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effects of telmisartan and valsartan as add-on agents for hypertensive patients with morning blood pressure insufficiently controlled by amlodipine monotherapy.
    Yoshida H; Akasaka H; Saitoh S; Shimamoto K; Miura T;
    Hypertens Res; 2014 Mar; 37(3):225-31. PubMed ID: 24108237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences.
    Miura Y; Yamamoto N; Tsunekawa S; Taguchi S; Eguchi Y; Ozaki N; Oiso Y
    Diabetes Care; 2005 Mar; 28(3):757-8. PubMed ID: 15735228
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.
    Rizos CV; Milionis HJ; Kostapanos MS; Florentin M; Kostara CE; Elisaf MS; Liberopoulos EN
    Clin Ther; 2010 Mar; 32(3):492-505. PubMed ID: 20399986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes.
    Suksomboon N; Poolsup N; Prasit T
    J Clin Pharm Ther; 2012 Jun; 37(3):319-27. PubMed ID: 21848583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations of insulin resistance and the serum adiponectin level in patients with type 2 diabetes mellitus under the usual antihypertensive dosage of telmisartan treatment.
    Fuke Y; Fujita T; Satomura A; Wada Y; Matsumoto K
    Diabetes Technol Ther; 2010 May; 12(5):393-8. PubMed ID: 20388049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus.
    Ozaki N; Nomura Y; Sobajima H; Kondo K; Oiso Y
    Eur J Intern Med; 2010 Jun; 21(3):236-9. PubMed ID: 20493430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine.
    Henderson DC; Fan X; Sharma B; Copeland PM; Borba CP; Freudenreich O; Cather C; Evins AE; Goff DC
    J Psychiatr Pract; 2009 Jul; 15(4):251-61. PubMed ID: 19625881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients.
    Hu S; Yao M; Peterson BS; Xu D; Hu J; Tang J; Fan B; Liao Z; Yuan T; Li Y; Yue W; Wei N; Zhou W; Huang M; Xu Y
    Psychopharmacology (Berl); 2013 Nov; 230(1):3-13. PubMed ID: 23559220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.